Celcuity (NASDAQ:CELC) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Celcuity (NASDAQ:CELC – Free Report) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday,Zacks reports.

A number of other research firms have also commented on CELC. HC Wainwright reduced their price objective on Celcuity from $155.00 to $150.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. Citigroup restated a “market outperform” rating on shares of Celcuity in a research note on Monday, November 9th. Needham & Company LLC decreased their price target on shares of Celcuity from $140.00 to $134.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Guggenheim started coverage on Celcuity in a research report on Friday, November 6th. They issued a “buy” rating and a $169.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $151.79.

Read Our Latest Report on CELC

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $55.60 on Tuesday. The business’s fifty day moving average price is $70.38 and its two-hundred day moving average price is $97.42. Celcuity has a fifty-two week low of $53.54 and a fifty-two week high of $151.02. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -11.80 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a current ratio of 14.62 and a quick ratio of 14.59.

Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.30. As a group, analysts predict that Celcuity will post -5.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC bought a new stake in Celcuity in the first quarter valued at approximately $38,000. PNC Financial Services Group Inc. boosted its position in shares of Celcuity by 20.1% during the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock worth $59,000 after purchasing an additional 86 shares in the last quarter. KBC Group NV acquired a new position in shares of Celcuity in the 1st quarter valued at $64,000. IFP Advisors Inc bought a new stake in shares of Celcuity in the 2nd quarter valued at $73,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of Celcuity by 139.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 820 shares of the company’s stock valued at $94,000 after buying an additional 477 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Trending Headlines about Celcuity

Investors following CELC have been watching these headlines:

  • Positive Sentiment: HC Wainwright kept its Buy rating and $150 price target. It also modestly improved its Q3 2027 EPS estimate to a loss of $0.73 per share from a loss of $0.80. MarketBeat coverage
  • Negative Sentiment: The larger revisions were downward: HC Wainwright now expects a 2026 loss of $5.23 per share, versus $4.84 previously, and a 2027 loss of $3.87, versus $3.10. It also raised projected losses for Q4 2026 and each of the first, second, and fourth quarters of 2027.
  • Negative Sentiment: Longer-term earnings expectations were cut substantially: the 2028 forecast shifted from $0.92 profit to a $1.38 loss; 2029 profit was reduced from $3.78 to $1.32 per share; and 2030 profit was lowered from $7.21 to $4.00. These changes suggest a slower path to profitability and are the clearest potential headwind for CELC. MarketBeat coverage

About Celcuity

(Get Free Report)

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

See Also

Analyst Recommendations for Celcuity (NASDAQ:CELC)

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.